Conversely, a study of 134 cognitively unimpaired women (mean age 65.95 years) enrolled in the Wisconsin Registry for Alzheimer's Prevention (WRAP) cohort study reported that HRT users who were APOE ε4 carriers (n = 27) had higher AD biomarker concentrations (phosphorylated tau [p‐tau]/amyloid beta [Aβ]42 ratio and Aβ42/Aβ40 ratio) compared to non–APOE ε4 carriers (n = 53).232. This evidence concerns the gene MAPT and Alzheimer disease.